Executive Committee
The Alliance Executive Committee serves as the Alliance’s principal body for scientific and operational leadership. Chaired by the Group Chair, it includes the Group Vice Chair, Program Directors, and eight Board of Directors representatives—four Principal Investigators from academic member institutions and four from community member institutions. The Executive Committee sets the Group’s scientific agenda by approving protocols at the concept stage, approves the appointment of Disease and Modality Committee Chairs, and oversees the management of Group affairs.
Group Chair
Evanthia Galanis, MD, DSc
Professor of Oncology, the Sandra J. Schulze Professor of Novel Therapeutics, and the Executive Dean for Development at Mayo Clinic
Dr. Galanis provides overall scientific, operational, and administrative leadership for the Alliance, guiding the research agenda and supporting the development and conduct of innovative cancer clinical trials. An internationally recognized clinician-investigator, she has led numerous cooperative group phase II and randomized clinical trials and has a longstanding commitment to developing novel therapeutic approaches for cancer.
Group VIce Chair
David E. Kozono, MD, PhD
Associate Professor of Radiation Oncology at Harvard Medical School and Director of Thoracic Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center
Dr. Kozono works closely with the Group Chair to guide the Alliance’s scientific priorities, organizational strategy, and research mission. He specializes in the treatment of thoracic malignancies, including lung cancer, and is committed to translating scientific discoveries into the design and conduct of innovative clinical trials with strong translational medicine objectives.
Program Principal Investigators
Program principal investigators direct the scientific, administrative, and operational activities of the Alliance’s five core research programs under the guidance of the Group Chair.
Executive Committee Members
Through regular collaboration, the Executive Committee members evaluate emerging scientific opportunities, establish research priorities, oversee operational performance, and guide decisions that advance the Alliance’s clinical research network. Together, they bring perspectives from across the organization to align scientific innovation, operational excellence, and multidisciplinary collaboration in support of the Alliance research mission.
Executive Committee
Abigail Caudle, MD
University of Texas MD Anderson Cancer Center LAPS
Executive Committee
Konstantin Dragnev, MD
Dartmouth College-Dartmouth Cancer Center LAPS
Executive Committee
Bryan Faller, MD
Heartland Cancer Research NCORP
Executive Committee
William Irvin Jr., MD
Southeast Clinical Oncology Research Consortium NCORP
Executive Committee
Gregory Masters, MD
Delaware/Christiana Care NCI Community Oncology Research Program
Executive Committee
Matthew Milowsky, MD
UNC Lineberger Comprehensive Cancer Center
Executive Committee
Ronica Nanda, MD
Morton Plant Hospital
Executive Committee
Claire Verschraegen, MD, MS
Ohio State University Comprehensive Cancer Center LAPS
Ad Hoc Representative
Steven Piantadosi, MD, PhD, FAACR
Alliance for Clinical Trials in Oncology
Ad Hoc Representative
Patty Spears
Alliance for Clinical Trials in Oncology
Ad Hoc Representative
Mark Watson, MD, PhD
Washington University School of Medicine LAPS
Liaison – Administrative
Kimberly Kerstann, PhD
Alliance for Clinical Trials in Oncology